Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Chenodeoxycholic Acid-Amikacin Combination Enhances Eradication of Staphylococcus aureus.

Tytuł:
Chenodeoxycholic Acid-Amikacin Combination Enhances Eradication of Staphylococcus aureus.
Autorzy:
Cui K; Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing, China.
Yang W; Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing, China.
Liu Z; Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Liu G; Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Li D; Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing, China.
Sun Y; Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing, China.
He G; Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing, China.
Ma S; Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing, China.
Cao Y; Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Jiang X; Beijing University of Chinese Medicine, Beijing, China.
Chevalier S; Normandy University, University of Rouen Normandy, Laboratory of Microbiology Signals and Microenvironment, Evreux, France.
Cornelis P; Normandy University, University of Rouen Normandy, Laboratory of Microbiology Signals and Microenvironment, Evreux, France.
Wei Q; Nanchang Institute of Technology, Nanchang, Jiangxi, China.
Wang Y; Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing, China.
Źródło:
Microbiology spectrum [Microbiol Spectr] 2023 Feb 14; Vol. 11 (1), pp. e0243022. Date of Electronic Publication: 2023 Jan 10.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Original Publication: Washington, DC : ASM Press, 2013-
MeSH Terms:
Methicillin-Resistant Staphylococcus aureus*
Staphylococcal Infections*/drug therapy
Animals ; Mice ; Staphylococcus aureus ; Amikacin/pharmacology ; Reactive Oxygen Species ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Aminoglycosides/pharmacology ; Aminoglycosides/therapeutic use ; Superoxide Dismutase/pharmacology ; Superoxide Dismutase/therapeutic use ; Microbial Sensitivity Tests
References:
Nat Biotechnol. 2013 Feb;31(2):160-5. (PMID: 23292609)
Org Lett. 2000 Sep 7;2(18):2837-40. (PMID: 10964378)
Annu Rev Pathol. 2016 May 23;11:343-64. (PMID: 26925499)
Front Microbiol. 2020 Dec 22;11:610070. (PMID: 33414777)
Org Biomol Chem. 2008 Feb 21;6(4):657-69. (PMID: 18354842)
Nat Microbiol. 2016 Apr 18;1:16051. (PMID: 27572649)
Mol Microbiol. 2014 Oct;94(1):172-85. (PMID: 25115812)
Cell. 2007 Sep 7;130(5):797-810. (PMID: 17803904)
PLoS One. 2011;6(12):e29276. (PMID: 22195037)
Trends Microbiol. 2015 Jul;23(7):437-44. (PMID: 25864883)
Antimicrob Agents Chemother. 2020 Nov 17;64(12):. (PMID: 33139283)
Nat Chem Biol. 2011 Jun;7(6):348-50. (PMID: 21516114)
J Antimicrob Chemother. 2001 May;47(5):671-4. (PMID: 11328782)
Acc Chem Res. 2008 Oct;41(10):1233-40. (PMID: 18616297)
BMC Complement Altern Med. 2018 May 30;18(1):169. (PMID: 29848316)
Arch Med Sci. 2011 Jun;7(3):414-22. (PMID: 22295022)
Front Cell Infect Microbiol. 2022 Apr 27;12:884045. (PMID: 35573768)
Adv Sci (Weinh). 2020 Jul 21;7(17):2001374. (PMID: 32995131)
J Antimicrob Chemother. 2012 Jun;67(6):1405-7. (PMID: 22382468)
Nat Rev Microbiol. 2019 Mar;17(3):141-155. (PMID: 30683887)
Front Microbiol. 2020 Dec 17;11:517462. (PMID: 33391189)
Science. 2011 Nov 18;334(6058):982-6. (PMID: 22096200)
Front Cell Infect Microbiol. 2020 Aug 05;10:396. (PMID: 32850494)
Nat Microbiol. 2018 Aug;3(8):881-890. (PMID: 30013237)
Clin Microbiol Infect. 2020 Jul;26(7):943.e1-943.e6. (PMID: 31812771)
J Altern Complement Med. 2010 Dec;16(12):1309-19. (PMID: 21091297)
J Ethnopharmacol. 2011 Mar 8;134(1):165-70. (PMID: 21182923)
Proc Natl Acad Sci U S A. 1974 Oct;71(10):3896-900. (PMID: 4279406)
Front Microbiol. 2020 Feb 14;11:25. (PMID: 32117092)
Curr Opin Pharmacol. 2019 Oct;48:92-98. (PMID: 31454708)
N Engl J Med. 1998 Aug 20;339(8):520-32. (PMID: 9709046)
Chem Biol. 2013 Sep 19;20(9):1168-78. (PMID: 23972939)
Am J Transl Res. 2019 Dec 15;11(12):7300-7309. (PMID: 31934279)
Biomed Chromatogr. 2019 Jul;33(7):e4531. (PMID: 30849182)
Evid Based Complement Alternat Med. 2016;2016:5292346. (PMID: 27366191)
PLoS Pathog. 2020 Dec 22;16(12):e1009126. (PMID: 33351859)
Crit Care. 2018 Dec 17;22(1):343. (PMID: 30558658)
Clin Infect Dis. 2008 Jun 1;46 Suppl 5:S350-9. (PMID: 18462090)
Elife. 2019 Aug 16;8:. (PMID: 31418687)
Am J Respir Crit Care Med. 2020 Feb 15;201(4):469-477. (PMID: 31647877)
Int J Food Microbiol. 2000 Sep 25;60(2-3):153-61. (PMID: 11016605)
Nature. 2021 Nov;599(7885):458-464. (PMID: 34325466)
Proc Natl Acad Sci U S A. 2009 Aug 25;106(34):14570-5. (PMID: 19706543)
Nat Microbiol. 2019 Apr;4(4):565-577. (PMID: 30833727)
J Clin Invest. 2009 Sep;119(9):2464-74. (PMID: 19729844)
Science. 2017 Mar 17;355(6330):1206-1211. (PMID: 28302858)
Clin Infect Dis. 2008 Jun 1;46 Suppl 5:S360-7. (PMID: 18462091)
Nat Rev Chem. 2021;5(10):726-749. (PMID: 34426795)
Lancet Respir Med. 2019 Dec;7(12):1027-1038. (PMID: 31727592)
Nature. 2011 May 12;473(7346):216-20. (PMID: 21562562)
Gastroenterology. 2009 Oct;137(4):1310-1320.e1-3. (PMID: 19622360)
Sci Rep. 2021 Mar 4;11(1):5116. (PMID: 33664307)
Nature. 2019 Dec;576(7785):143-148. (PMID: 31776512)
Cell. 2020 Jun 25;181(7):1518-1532.e14. (PMID: 32497502)
Nat Rev Microbiol. 2013 Jul;11(7):443-54. (PMID: 23712352)
Cell Host Microbe. 2019 Jul 10;26(1):61-72. (PMID: 31295426)
J Antimicrob Chemother. 2017 Jun 1;72(6):1723-1730. (PMID: 28333193)
Cell Chem Biol. 2019 Oct 17;26(10):1355-1364.e4. (PMID: 31402316)
Lancet Infect Dis. 2001 Oct;1(3):147-55. (PMID: 11871491)
J Ethnopharmacol. 2020 Feb 10;248:112272. (PMID: 31586695)
Nature. 2013 Nov 21;503(7476):365-70. (PMID: 24226776)
Front Microbiol. 2019 Jan 28;10:41. (PMID: 30745898)
Contributed Indexing:
Keywords: Staphylococcus aureus; antibiotic resistance; chenodeoxycholic acid; dual mechanism; traditional Chinese medicine
Substance Nomenclature:
84319SGC3C (Amikacin)
0 (Reactive Oxygen Species)
0 (Anti-Bacterial Agents)
0 (Aminoglycosides)
EC 1.15.1.1 (Superoxide Dismutase)
Entry Date(s):
Date Created: 20230110 Date Completed: 20230216 Latest Revision: 20231020
Update Code:
20240105
PubMed Central ID:
PMC9927322
DOI:
10.1128/spectrum.02430-22
PMID:
36625660
Czasopismo naukowe
The rise of antibiotic resistance and dearth of novel antibiotics have posed a serious health crisis worldwide. In this study, we screened a combination of antibiotics and nonantibiotics providing a viable strategy to solve this issue by broadening the antimicrobial spectrum. We found that chenodeoxycholic acid (CDCA), a cholic acid derivative of the traditional Chinese medicine (TCM) Tanreqing (TRQ), synergizes with amikacin against Staphylococcus aureus in vitro , and this synergistic killing was effective against diverse methicillin-resistant S. aureus (MRSA) variants, including small-colony variants (SCVs), biofilm strains, and persisters. The CDCA-amikacin combination protects a mouse model from S. aureus infections. Mechanistically, CDCA increases the uptake of aminoglycosides in a proton motive force-dependent manner by dissipating the chemical potential and potentiates reactive oxygen species (ROS) generation by inhibiting superoxide dismutase activity. This work highlights the potential use of TCM components in treating S. aureus-associated infections and extend the use of aminoglycosides in eradicating Gram-positive pathogens. IMPORTANCE Multidrug resistance (MDR) is spreading globally with increasing speed. The search for new antibiotics is one of the key strategies in the fight against MDR. Antibiotic resistance breakers that may or may not have direct antibacterial action and can either be coadministered or conjugated with other antibiotics are being studied. To better expand the antibacterial spectrum of certain antibiotics, we identified one component from a traditional Chinese medicine, Tanreqing (TRQ), that increased the activity of aminoglycosides. We found that this so-called agent, chenodeoxycholic acid (CDCA), sensitizes Staphylococcus aureus to aminoglycoside killing and protects a mouse model from S. aureus infections. CDCA increases the uptake of aminoglycosides in a proton motive force-dependent manner by dissipating the chemical potential and potentiates ROS generation by inhibiting superoxide dismutase activity in S. aureus. Our work highlights the potential use of TCM or its effective components, such as CDCA, in treating antibiotic resistance-associated infections.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies